Clairvoyant Therapeutics: First Patient Dosed in Clairvoyant's Phase 2 Clinical Trial Exploring Psilocybin as a Treatment for Alcohol Use Disorder
VANCOUVER, BC / ACCESSWIRE / November 3, 2022 / Clairvoyant Therapeutics ("Clairvoyant"), a clinical stage biotech company focused on the development of psychedelic drug therapies for the treatment of